---
title: CDMO Daily News — September 26, 2026
slug: daily-news-2026-09-26-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: September 26 CDMO daily: Altruist Biologics Suzhou Facility Achieves First EMA GMP Certification; SK pharmteco Launches Catalyst Kit for Continuous API…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-09-26-cdmo
published_at: 2026-09-26T00:00:24.943Z
last_updated: 2026-09-26T00:02:57.502Z
---

### [Altruist Biologics](/companies/altruist-biologics) Suzhou Facility Achieves First EMA GMP Certification
- [Altruist Biologics](/companies/altruist-biologics)' Suzhou commercial manufacturing facility passed EMA GMP inspection with zero critical findings, supporting an EU marketing authorization for a biologics client.
- The 60,000-liter antibody facility underwent comprehensive assessment of quality systems, data integrity, and operational performance across the full manufacturing lifecycle.
- Altruist now operates 140,000 liters of CDMO capacity across Suzhou and Hangzhou sites, with planned expansion to 232,000 liters by mid-2027.

**Operational Impact**

Altruist's Suzhou EMA certification removes a regulatory barrier for EU-bound biologics programs and signals readiness for commercial-scale antibody and ADC manufacturing in APAC, supporting clients navigating multi-region technology transfer.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/altruist-biologics-suzhou-facility-passes-ema-gmp-inspection)*

---

### [SK pharmteco](/companies/skpharmteco) Launches Catalyst Kit for Continuous API Manufacturing
- [SK pharmteco](/companies/skpharmteco) introduced a three-stage Catalyst Kit program to guide clients from catalyst screening through commercial-scale continuous fixed-bed reactor (FBR) development for APIs, intermediates, and registered starting materials.
- The program provides 12 catalyst samples in stage one, process optimization support in stage two, and GMP scale-up from kilo through multi-ton production in stage three.
- Continuous catalytic flow processing offers potential benefits including lower catalyst consumption, reduced solvent waste, longer catalyst life, and predictable scale-up for hydrogenation and high-pressure reactions.

**Operational Impact**

CDMO directors evaluating continuous manufacturing capabilities can now access [SK pharmteco](/companies/skpharmteco)'s catalyst screening and optimization services as a structured entry point, reducing development risk for hydrogenation and high-pressure catalytic processes destined for GMP scale-up.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/sk-pharmteco-launches-catalyst-kit-for-continuous-api-manufacturing)*

## References

1. [PharmaSource RSS — Altruist Biologics Suzhou Facility Achieves First EMA GMP Certification](https://pharmasource.global/content/news/cdmo-news/altruist-biologics-suzhou-facility-passes-ema-gmp-inspection)
2. [PharmaSource RSS — SK pharmteco Launches Catalyst Kit for Continuous API Manufacturing](https://pharmasource.global/content/news/cdmo-news/sk-pharmteco-launches-catalyst-kit-for-continuous-api-manufacturing)

Source: https://www.cdmo.directory/posts/daily-news-2026-09-26-cdmo